The DOI matches its Crossref record; 71 of the 71 references it cites were found in a registry or an index.
Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease
Open accessAbstract
The pathophysiological process of Alzheimer's disease (AD) is thought to begin many years before the diagnosis of AD dementia. This long “preclinical” phase of AD would provide a critical opportunity for therapeutic intervention; however, we need to further elucidate the link between the pathological cascade of AD and the emergence of clinical symptoms. The National Institute on Aging and the Alzheimer's Association convened an international workgroup to review the biomarker, epidemiological, and neuropsychological evidence, and to develop recommendations to determine the factors which best predict the risk of progression from “normal” cognition to mild cognitive impairment and AD dementia. We propose a conceptual framework and operational research criteria, based on the prevailing scientific evidence to date, to test and refine these models with longitudinal clinical research studies. These recommendations are solely intended for research purposes and do not have any clinical implications at this time. It is hoped that these recommendations will provide a common rubric to advance the study of preclinical AD, and ultimately, aid the field in moving toward earlier intervention at a stage of AD when some disease‐modifying therapies may be most efficacious.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The susceptibility of the conventional criteria for MCI to diagnostic error is likely to be amplified if used to characterize and stage preclinical AD—a pre-MCI categorization based on subtle cognitive decline [8].”
From Neuropsychological Criteria for Mild Cognitive Impairment Improves Diagnostic Precision, Biomarker Associations, and Progression Rates (2014) · cites this paper as [8]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In PET imaging, PIB and Florbetapir (AV45) amyloid tracers have shown greater cortical uptake in patients diagnosed with AD compared with control participants 11,57 .”
From OASIS-3: Longitudinal Neuroimaging, Clinical, and Cognitive Dataset for Normal Aging and Alzheimer Disease (2019) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Several anti-Aβ therapeutic strategies are being pursued to treat AD; however, it is likely that treatment will need to begin during the preclinical phase to prevent or limit plaque accumulation to be beneficial in reducing the risk of developing AD (51, 52).”
From Serotonin signaling is associated with lower amyloid-β levels and plaques in transgenic mice and humans (2011) · cites this paper as [52]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“New clinical diagnostic consensus criteria have now been finalized under the auspices of the NIA and Alzheimer's Association (52), with novel features including recognition of a preclinical stage of AD and the incorporation of imaging and laboratory-based cerebrospinal fluid biomarkers.”
From Accuracy of the Clinical Diagnosis of Alzheimer Disease at National Institute on Aging Alzheimer Disease Centers, 2005–2010 (2012) · cites this paper as [52]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Alzheimer’s disease (AD) begins several decades before the clinical onset of dementia with progressive amyloid accumulation preceding significant tau pathology and neurodegeneration.10,11”
From Machine learning reveals prominent spontaneous behavioral changes and treatment efficacy in humanized and transgenic Alzheimer's disease models (2024) · cites this paper as [11]
Experimental — accuracy not yet measured
The cited source says what the claim attributes to it.
In the citing paper
“Because there is evidence that the pathophysiology of AD likely begins many years before the emergence of clinical symptoms or a syndrome such as MCI or dementia”
From The Need to Separate Chronic Traumatic Encephalopathy Neuropathology from Clinical Features (2017) · cites this paper as [102]
The cited source says what the claim attributes to it.
In the citing paper
“Nevertheless, after decades of research, both the etiology and the pathophysiologic sequence of AD remain uncertain [102]”
From The Need to Separate Chronic Traumatic Encephalopathy Neuropathology from Clinical Features (2017) · cites this paper as [102]
The cited source says what the claim attributes to it.
In the citing paper
“This unifying research framework is a natural descendant of the 2011 NIA-AA preclinical AD recommendations that were based on the concept that AD, identified by biomarkers, can exist in the absence of symptoms [4].”
From NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease (2018) · cites this paper as [4]
The cited source says what the claim attributes to it.
In the citing paper
“Clinico-pathologic correlations for individuals without cognitive impairment should indicate that it is possible for AD neuropathologic change to predate onset of symptoms by years [54].”
From National Institute on Aging–Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease: a practical approach (2012) · cites this paper as [54]
The cited source says what the claim attributes to it.
In the citing paper
“recognition that AD neuropathologic changes may occur in the apparent absence of cognitive impairment”
From National Institute on Aging–Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease: a practical approach (2012) · cites this paper as [54]
The cited source says what the claim attributes to it.
In the citing paper
“This later point is important as the pathophysiological changes in the brain of people with AD require several years to occur.16”
From Cumulative Use of Strong Anticholinergics and Incident Dementia: A Prospective Cohort Study (2015) · cites this paper as [16]
The cited source says what the claim attributes to it.
In the citing paper
“The timing of therapeutic treatment in AD seems to be crucial as studies have shown that treating the disease too late has little efficacy (Sperling et al., 2011; Yiannopoulou et al., 2019).”
From Inhibiting USP16 rescues stem cell aging and memory in an Alzheimer’s model (2022) · cites this paper as Sperling et al., 2011
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“But their high cost and insufficient accessibility are being major limitations [12].”
From Integrated analysis of ultra-deep proteomes in cortex, cerebrospinal fluid and serum reveals a mitochondrial signature in Alzheimer’s disease (2020) · cites this paper as [12]
Experimental — accuracy not yet measuredIn the citing paper
“individuals remain cognitively normal for many years despite accumulating aggregates of Aβ plaques and tau neurofibrillary tangles (Sperling et al., 2011).”
From A Multi-network Approach Identifies Protein-Specific Co-expression in Asymptomatic and Symptomatic Alzheimer’s Disease (2017) · cites this paper as Sperling et al., 2011
In the citing paper
“The neuropathological changes of Alzheimer’s disease (AD) begin two decades or more before signs of cognitive impairment (Sperling et al., 2011).”
From A Multi-network Approach Identifies Protein-Specific Co-expression in Asymptomatic and Symptomatic Alzheimer’s Disease (2017) · cites this paper as Sperling et al., 2011
In the citing paper
“Additionally, we used the old criteria for the preclinical AD definition, while the recent research criteria also require tau positivity [8].”
From Duration of preclinical, prodromal, and dementia stages of Alzheimer's disease in relation to age, sex, and APOE genotype (2019) · cites this paper as [8]
In the citing paper
“Plaque formation rates also vary over time [217]. After a period of rapid accumulation, plaque deposition gradually slows and by the time symptoms manifest plaque deposition is essentially done [20, 205, 218].”
From The Alzheimer’s disease mitochondrial cascade hypothesis: progress and perspectives (2014) · cites this paper as [20]
In the citing paper
“The amyloid cascade hypothesis [14, 15], in conjunction with the newly designated preclinical AD category [20], necessarily infers cognitive changes that arise before plaques appear are etiologically unrelated to cognitive changes that arise after plaques appear.”
From The Alzheimer’s disease mitochondrial cascade hypothesis: progress and perspectives (2014) · cites this paper as [20]
In the citing paper
“In addition to using Aβ phenomena to distinguish AD from “normal” brain aging, the new criteria make one critical mechanistic assumption. Aβ is identified as an “upstream” AD biomarker [77]. Other biomarkers, including increased CSF tau, CSF phospho-tau, and decreased glucose utilization (as demonstrated by fluorodeoxyglucose PET; FDG PET), are identified as “downstream” biomarkers.”
From Brain aging, Alzheimer's disease, and mitochondria (2011) · cites this paper as [77]
In the citing paper
“According to the new AD diagnostic criteria cognitive decline and an absence of alternative dementia-associated pathology are no longer required features. At least for research purposes, to qualify for a diagnosis of AD altered brain or CSF Aβ is now the sole requirement [77].”
From Brain aging, Alzheimer's disease, and mitochondria (2011) · cites this paper as [77]
In the citing paper
“This is reflected by the recent adoption of AD diagnostic criteria that classify cognitively normal individuals with brain plaques or low cerebrospinal fluid Aβ levels as having “preclinical AD” [77].”
From Brain aging, Alzheimer's disease, and mitochondria (2011) · cites this paper as [77]
In the citing paper
“Studies of non-demented elderly cohorts overall report approximately 20–40% are PIB-positive [67, 68, 71–78].”
From Brain aging, Alzheimer's disease, and mitochondria (2011) · cites this paper as [77]
In the citing paper
“According to the new criteria, the primary dividing line between AD and brain aging is the presence or absence of brain or CSF Aβ changes.”
From Brain aging, Alzheimer's disease, and mitochondria (2011) · cites this paper as [77]
In the citing paper
“This asymptomatic phase of AD (AsymAD) is currently considered a preclinical stage of the disease [27, 28].”
From Deep proteomic network analysis of Alzheimer’s disease brain reveals alterations in RNA binding proteins and RNA splicing associated with disease (2018) · cites this paper as [28]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
Self-citationNeuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123 · cited 1×
“ries [68]) and the clinical syndrome of AD dementia (estimated prevalence from three epidemiological studies [69–71]).”
BackgroundAlbert, M. S., DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., Gamst, A., Holtzman, D. M., Jagust, W. J., Petersen, R. C., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.008 · Cited by 10,152 · cited 1×
“This long “preclinical” phase of AD would provide a critical opportunity for therapeutic intervention; however, we need to further elucidate the link between the pathological cascade of AD and the emergence of clinical symptoms.”
BackgroundSelf-citationHypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
Jack, C. R., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., Petersen, R. C., & Trojanowski, J. Q. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70299-6 · Cited by 4,806
Self-citationAlzheimer's Disease Is a Synaptic Failure
Selkoe, D. J. (2002) · Science · doi:10.1126/science.1074069 · Cited by 4,420
Shankar, G. M., Li, S., Mehta, T. H., Garcia-Munoz, A., Shepardson, N. E., Smith, I., Brett, F. M., Farrell, M. A., Rowan, M. J., Lemere, C. A., et al. (2008) · Nature Medicine · doi:10.1038/nm1782 · Cited by 3,685
Stern, Y. (2009) · Neuropsychologia · doi:10.1016/j.neuropsychologia.2009.03.004 · Cited by 2,943
Self-citationDecreased Clearance of CNS β-Amyloid in Alzheimer’s Disease
Mawuenyega, K. G., Sigurdson, W., Ovod, V., Munsell, L., Kasten, T., Morris, J. C., Yarasheski, K. E., & Bateman, R. J. (2010) · Science · doi:10.1126/science.1197623 · Cited by 2,078
Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects
Shaw, L. M., Vanderstichele, H., Knapik‐Czajka, M., Clark, C. M., Aisen, P. S., Petersen, R. C., Blennow, K., Soares, H., Simon, A., Lewczuk, P., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21610 · Cited by 2,065
Self-citationJack, C. R., Albert, M. S., Knopman, D. S., McKhann, G. M., Sperling, R. A., Carrillo, M. C., Thies, B., & Phelps, C. H. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.004 · Cited by 2,042
Self-citation
Research works printed but not linked: 1
- JABecker DRentz JSCarmasin THedden IHamdi RLBuckner et al.Amyloid deposition and brain volume across the continuum of aging and AD.Ann Neurol2011(in press)
Cited by
Sorted by citations
Items 901–1,000 of 1,158
Personality and Alzheimer’s disease: An integrative review.
Terracciano, A., & Sutin, A. R. (2019) · Personality Disorders Theory Research and Treatment · doi:10.1037/per0000268 · Cited by 112
Fišar, Z. (2022) · Biomolecules · doi:10.3390/biom12111676 · Cited by 113
Caselli, R. J., & Reiman, E. M. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-129026 · Cited by 111
Self-citationQiu, S., Chang, G. H., Panagia, M., Gopal, D. M., Au, R., & Kolachalama, V. B. (2018) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1016/j.dadm.2018.08.013 · Cited by 110
Leibson, C. L., Long, K. H., Ransom, J. E., Roberts, R. O., Hass, S. L., Duhig, A. M., Smith, C. Y., Emerson, J. A., Pankratz, V. S., & Petersen, R. C. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2015.01.007 · Cited by 110
Aβ-amyloid and Tau Imaging in Dementia
Villemagne, V. L., Doré, V., Bourgeat, P., Burnham, S. C., Laws, S., Salvado, O., Masters, C. L., & Rowe, C. C. (2017) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2016.09.006 · Cited by 110
Self-citationSelective changes in white matter integrity in MCI and older adults with cognitive complaints
Wang, Y., West, J. D., Flashman, L. A., Wishart, H. A., Santulli, R. B., Rabin, L. A., Pare, N., Arfanakis, K., & Saykin, A. J. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2011.08.002 · Cited by 110
Is amyloid-β harmful to the brain? Insights from human imaging studies
Jagust, W. (2016) · Brain · doi:10.1093/brain/awv326 · Cited by 110
Tau Positron Emission Tomography (PET) Imaging: Past, Present, and Future
Ariza, M., Kolb, H. C., Moechars, D., Rombouts, F. J. R., & Andrés, J. I. (2015) · Journal of Medicinal Chemistry · doi:10.1021/jm5017544 · Cited by 110
Vascular Risk and β ‐Amyloid Are Synergistically Associated with Cortical Tau
Rabin, J. S., Yang, H., Schultz, A. P., Hanseeuw, B. J., Hedden, T., Viswanathan, A., Gatchel, J. R., Marshall, G. A., Kilpatrick, E. P., Klein, H., et al. (2018) · Annals of Neurology · doi:10.1002/ana.25399 · Cited by 110
Self-citationAnalysis of Salivary Microbiome in Patients with Alzheimer’s Disease
Liu, X., Jiao, B., Liao, X., Guo, L., Yuan, Z., Wang, X., Xiao, X., Zhang, X., Tang, B., & Shen, L. H. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-190587 · Cited by 110
Therapeutic potential of astaxanthin and superoxide dismutase in Alzheimer's disease
Balendra, V., & Singh, S. K. (2021) · Open Biology · doi:10.1098/rsob.210013 · Cited by 111
Memory complaints and risk of cognitive impairment after nearly 2 decades among older women
Kaup, A. R., Nettiksimmons, J., LeBlanc, E. S., & Yaffe, K. (2015) · Neurology · doi:10.1212/wnl.0000000000002153 · Cited by 109
Self-citationSuárez‐Calvet, M., Capell, A., Araque Caballero, M. Á., Morenas‐Rodríguez, E., Fellerer, K., Franzmeier, N., Kleinberger, G., Eren, E., Deming, Y., Piccio, L., et al. (2018) · EMBO Molecular Medicine · doi:10.15252/emmm.201809712 · Cited by 109
Self-citationAPOE-related biomarker profiles in non-pathological aging and early phases of Alzheimer's disease
Reinvang, I., Espeseth, T., & Westlye, L. T. (2013) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2013.05.006 · Cited by 109
Ishii, M., Wang, G., Racchumi, G., Dyke, J. P., & Iadecola, C. (2014) · Journal of Neuroscience · doi:10.1523/jneurosci.0872-14.2014 · Cited by 109
Stronger effect of amyloid load than APOE genotype on cognitive decline in healthy older adults
Lim, Y. Y., Ellis, K. A., Pietrzak, R. H., Ames, D. J., Darby, D., Harrington, K., Martins, R. N., Masters, C. L., Rowe, C. C., Savage, G. R., et al. (2012) · Neurology · doi:10.1212/wnl.0b013e31826e9ae6 · Cited by 109
Self-citationIncreased fragmentation of sleep–wake cycles in the 5XFAD mouse model of Alzheimer’s disease
Sethi, M., Joshi, S., Webb, R. L., Beckett, T. L., Donohue, K. D., Murphy, M. P., O’Hara, B. F., & Duncan, M. J. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2015.01.035 · Cited by 109
Melah, K. E., Lu, S. Y.-F., Hoscheidt, S. M., Alexander, A. L., Adluru, N., Destiche, D. J., Carlsson, C. M., Zetterberg, H., Blennow, K., Okonkwo, O. C., et al. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-150897 · Cited by 109
Association of Longitudinal Cognitive Decline With Amyloid Burden in Middle-aged and Older Adults
Farrell, M. E., Kennedy, K. M., Rodrigue, K. M., Wig, G. S., Bischof, G. N., Rieck, J. R., Chen, X., Festini, S. B., Devous, M. D., & Park, D. C. (2017) · JAMA Neurology · doi:10.1001/jamaneurol.2017.0892 · Cited by 109
Self-citationLejri, I., Agapouda, A., Grimm, A., & Eckert, A. (2019) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2019/9695412 · Cited by 109
Subjective Cognitive Decline and Related Cognitive Deficits
Si, T., Xing, G., & Han, Y. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.00247 · Cited by 109
Accelerated functional brain aging in pre-clinical familial Alzheimer’s disease
Gonneaud, J., Baria, A. T., Binette, A. P., Gordon, B. A., Chhatwal, J. P., Cruchaga, C., Jucker, M., Levin, J., Salloway, S., Farlow, M. R., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25492-9 · Cited by 109
Self-citationOlichney, J., Yang, J.-C., Taylor, J. R., & Marta Kutas, A. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-0047 · Cited by 109
Alosco, M. L., Tripodis, Y., Jarnagin, J., Baugh, C. M., Martin, B. M., Chaisson, C. E., Estochen, N., Song, L., Cantu, R. C., Jeromin, A., et al. (2016) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2016.11.003 · Cited by 109
Galea, E., Launay, N., Portero-Otin, M., Ruiz, M., Pamplona, R., Aubourg, P., Ferrer, I., & Pujol, A. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2012.02.005 · Cited by 108
Diagnostic accuracy of CSF Ab42 and florbetapir PET for Alzheimer's disease
Mattsson, N., Insel, P. S., Landau, S. M., Jagust, W., Donohue, M., Shaw, L. M. J., Trojanowski, J. Q., Zetterberg, H., Blennow, K., Weiner, M. W., et al. (2014) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.81 · Cited by 108
Kaur, U., Banerjee, P., Bir, A., Sinha, M. S., Biswas, A., & Chakrabarti, S. (2015) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026615666150114160543 · Cited by 109
Memory self-awareness in the preclinical and prodromal stages of Alzheimer’s disease
Vannini, P., Amariglio, R. E., Hanseeuw, B. J., Johnson, K. A., McLaren, D. G., Chhatwal, J. P., Pascual‐Leone, Á., Rentz, D. M., & Sperling, R. A. (2017) · Neuropsychologia · doi:10.1016/j.neuropsychologia.2017.04.002 · Cited by 108
Self-citationNicosia, J., Aschenbrenner, A. J., Balota, D. A., Sliwinski, M. J., Tahan, M., Adams, S., Stout, S. H., Wilks, H., Gordon, B. A., Benzinger, T. L. S., et al. (2022) · Journal of the International Neuropsychological Society · doi:10.1017/s135561772200042x · Cited by 108
Self-citationBeckett, L. A., Donohue, M., Wang, C., Aisen, P. S. S., Harvey, D. J., Saito, N. H., & Initiative, A. D. N. (2015) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2015.05.004 · Cited by 108
Self-citationAssessment of cognition in early dementia
Silverberg, N. B., Ryan, L. M., Carrillo, M. C., Sperling, R. A., Petersen, R. C., Posner, H. B., Snyder, P. J., Hilsabeck, R. C., Gallagher, M., Raber, J., et al. (2011) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2011.05.001 · Cited by 109
Self-citationPlasma 24-metabolite Panel Predicts Preclinical Transition to Clinical Stages of Alzheimer’s Disease
Fiandaca, M. S., Zhong, X., Cheema, A. K., Orquiza, M. H., Chidambaram, S., Tan, M. T., Gresenz, C. R., Fitzgerald, K. T., Nalls, M. A., Singleton, A., et al. (2015) · Frontiers in Neurology · doi:10.3389/fneur.2015.00237 · Cited by 107
Proton Pump Inhibitor Use and Dementia Risk: Prospective Population‐Based Study
Gray, S. L., Walker, R. L., Dublin, S., Yu, O., Bowles, E. J. A., Anderson, M. L., Crane, P. K., & Larson, E. B. (2017) · Journal of the American Geriatrics Society · doi:10.1111/jgs.15073 · Cited by 107
ATN profiles among cognitively normal individuals and longitudinal cognitive outcomes
Soldan, A., Pettigrew, C. A., Fagan, A. M., Schindler, S. E., Moghekar, A., Fowler, C. J., Li, Q.-X., Collins, S. J., Carlsson, C. M., Asthana, S., et al. (2019) · Neurology · doi:10.1212/wnl.0000000000007248 · Cited by 107
Self-citationAge and cognitive decline in the UK Biobank
Cornelis, M. C., Wang, Y., Holland, T. M., Agarwal, P., Weıntraub, S., & Morris, M. C. (2019) · PLoS ONE · doi:10.1371/journal.pone.0213948 · Cited by 107
Uzuegbunam, B. C., Librizzi, D., & Yousefi, B. H. (2020) · Molecules · doi:10.3390/molecules25040977 · Cited by 107
The Ontario Neurodegenerative Disease Research Initiative (ONDRI)
Farhan, S. M. K., Bartha, R., Black, S. E., Corbett, D., Finger, E. C., Freedman, M., Greenberg, B., Grimes, D. A., Hegele, R. A., Hudson, C., et al. (2016) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/cjn.2016.415 · Cited by 107
Preferential degradation of cognitive networks differentiates Alzheimer’s disease from ageing
Chhatwal, J. P., Schultz, A. P., Johnson, K. A., Hedden, T., Jaimes, S., Benzinger, T. L. S., Jack, C., Ances, B. M., Ringman, J. M., Marcus, D. S., et al. (2018) · Brain · doi:10.1093/brain/awy053 · Cited by 101
Self-citationKuruppu, D. K., & Matthews, B. R. (2013) · Seminars in Neurology · doi:10.1055/s-0033-1359320 · Cited by 106
Toledo, J. B., Korff, A., Shaw, L. M. J., Trojanowski, J. Q., & Zhang, J. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1148-z · Cited by 106
Ritchie, C. W., Terrera, G. M., & Quinn, T. J. (2015) · Alzheimer s Research & Therapy · doi:10.1186/s13195-015-0113-6 · Cited by 106
Mendivil‐Perez, M., Soto‐Mercado, V., Guerra‐Librero, A., Fernández-Gil, B. I., Florido, J., Shen, Y., Tejada, M. A., Capilla‐González, V., Rusanova, I., García‐Verdugo, J. M., et al. (2017) · Journal of Pineal Research · doi:10.1111/jpi.12415 · Cited by 106
Alzheimer's disease pathophysiology in the Retina
Gaire, B. P., Koronyo, Y., Fuchs, D.-T. S., Shi, H., Rentsendorj, A., Danziger, R., Vit, J., Mirzaei, N., Doustar, J., Sheyn, J., et al. (2024) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2024.101273 · Cited by 107
Macuco, C. R. M., Batistoni, S. S. T., Lopes, A., Cachioni, M., Falcão, D. V. D. S., Neri, A. L., & Yassuda, M. S. (2012) · International Psychogeriatrics · doi:10.1017/s1041610212000907 · Cited by 106
Apraxia and Alzheimer’s Disease: Review and Perspectives
Lesourd, M., Gall, D. L., Baumard, J., Croisile, B., Jarry, C., & Osiurak, F. (2013) · Neuropsychology Review · doi:10.1007/s11065-013-9235-4 · Cited by 106
Iulita, M. F., Allard, S. T. M., Richter, L., Munter, L. M., Ducatenzeiler, A., Weise, C., Carmo, S. D., Klein, W. L., Multhaup, G., & Cuello, A. C. (2014) · Acta Neuropathologica Communications · doi:10.1186/2051-5960-2-61 · Cited by 106
Redox proteomics and amyloid β-peptide: Insights into Alzheimer disease
Butterfield, D. A., & Boyd‐Kimball, D. (2019) · Journal of Neurochemistry · doi:10.1111/jnc.14589 · Cited by 105
Pannee, J., Portelius, E., Oppermann, M., Atkins, A., Hornshaw, M., Zegers, I., Höjrup, P., Minthon, L., Hansson, O., Zetterberg, H., et al. (2013) · Journal of Alzheimer’s Disease · doi:10.3233/jad-2012-121471 · Cited by 105
Gordon, B. A., Blazey, T., Su, Y., Fagan, A. M., Holtzman, D. M., Morris, J. C., & Benzinger, T. L. S. (2016) · JAMA Neurology · doi:10.1001/jamaneurol.2016.2642 · Cited by 105
Self-citationAltered whole-brain white matter networks in preclinical Alzheimer's disease
Fischer, F. U., Wolf, D., Scheurich, A., & Fellgiebel, A. (2015) · NeuroImage: Clinical · doi:10.1016/j.nicl.2015.06.007 · Cited by 105
Relation of neuropathology with cognitive decline among older persons without dementia
Boyle, P. A., Yu, L., Wilson, R. S., Schneider, J. A., & Bennett, D. A. (2013) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2013.00050 · Cited by 105
Self-citationIs the Amyloid Hypothesis of Alzheimer's disease therapeutically relevant?
Teich, A. F., & Arancio, O. (2012) · Biochemical Journal · doi:10.1042/bj20120653 · Cited by 105
Plasma Aβ but Not Tau is Related to Brain PiB Retention in Early Alzheimer’s Disease
Tzen, K., Yang, S., Chen, T., Cheng, T.-W., Horng, H. E., Wen, H.-P., Huang, Y.-Y., Shiue, C., & Chiu, M. (2014) · ACS Chemical Neuroscience · doi:10.1021/cn500101j · Cited by 105
European Prevention of Alzheimer’s Dementia Longitudinal Cohort Study (EPAD LCS): study protocol
Solomon, A., Kivipelto, M., Molinuevo, J. L., Tom, B. D. M., & Ritchie, C. W. (2018) · BMJ Open · doi:10.1136/bmjopen-2017-021017 · Cited by 105
Wirth, M., Schwarz, C., Benson, G. S., Horn, N., Buchert, R., Lange, C., Köbe, T., Hetzer, S., Maglione, M., Michael, E., et al. (2019) · Alzheimer s Research & Therapy · doi:10.1186/s13195-019-0484-1 · Cited by 105
Biochemical Markers in Alzheimer’s Disease
Rabbito, A., Dulewicz, M., Kulczyńska‐Przybik, A., & Mroczko, B. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21061989 · Cited by 105
Tomé, S. O., Vandenberghe, R. R., Ospitalieri, S., Schoor, E. V., Tousseyn, T., Otto, M., Arnim, C. A. F. V., & Thal, D. R. (2020) · Acta Neuropathologica Communications · doi:10.1186/s40478-020-00934-5 · Cited by 105
Insulin Resistance and Cognitive Impairment: Evidence From Neuroimaging
Cui, Y., Tang, T., Lu, C., & Ju, S. (2022) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.28358 · Cited by 105
Amyloid Burden in Obstructive Sleep Apnea
Yun, C., Lee, H., Lee, S. K., Kim, H., Seo, H. S., Bang, S. A., Kim, S. E., Greve, D. N., Au, R., Shin, C., et al. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-161047 · Cited by 105
Andersen, J. V., Skotte, N. H., Christensen, S. K., Polli, F. S., Shabani, M., Markussen, K. H., Haukedal, H., Westi, E. W., Diaz-delCastillo, M., Sun, R. C., et al. (2021) · Cell Death & Disease · doi:10.1038/s41419-021-04237-y · Cited by 104
Diffusion-MRI in neurodegenerative disorders
Goveas, J., O’Dwyer, L., Mascalchi, M., Cosottini, M., Diciotti, S., De Santis, S., Passamonti, L., Tessa, C., Toschi, N., & Giannelli, M. (2015) · Magnetic Resonance Imaging · doi:10.1016/j.mri.2015.04.006 · Cited by 104
Worldwide Alzheimer's Disease Neuroimaging Initiative
Carrillo, M. C., Bain, L. J., Frisoni, G. B., & Weiner, M. W. (2012) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2012.04.007 · Cited by 104
Self-citationMuszyński, P., Groblewska, M., Kulczyńska‐Przybik, A., Kułakowska, A., & Mroczko, B. (2017) · Current Neuropharmacology · doi:10.2174/1570159x15666170208124324 · Cited by 104
A brief history of “Alzheimer disease”
Knopman, D. S., Petersen, R. C., & Jack, C. R. (2019) · Neurology · doi:10.1212/wnl.0000000000007583 · Cited by 104
Self-citationSanabria-Díaz, G., Martínez‐Montes, E., Melie‐García, L., & Initiative, T. A. D. N. (2013) · PLoS ONE · doi:10.1371/journal.pone.0068860 · Cited by 104
Loewenstein, D., Curiel, R. E., Greig, M. T., Bauer, R. M., Rosado, M., Bowers, D., Wicklund, M. R., Crocco, E., Pontecorvo, M. J., Joshi, A. D., et al. (2016) · American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2016.02.056 · Cited by 104
Longitudinal brain structural changes in preclinical Alzheimer's disease
Pegueroles, J., Vilaplana, E., Montal, V., Sampedro, F., Alcolea, D. A., Carmona‐Iragui, M., Clarimón, J., Blesa, R., Lleó, A., Fortea, J., et al. (2016) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2016.08.010 · Cited by 106
CSF biomarker changes precede symptom onset of mild cognitive impairment
Moghekar, A., Li, S., Lu, Y., Li, M., Wang, M.-C., Albert, M., O’Brien, R., & For the BIOCARD Research Team (2013) · Neurology · doi:10.1212/01.wnl.0000435558.98447.17 · Cited by 103
Li, H., Liu, C.-C., Zheng, H., & Huang, T. Y. (2018) · Translational Neurodegeneration · doi:10.1186/s40035-018-0139-3 · Cited by 103
Selnes, P., Aarsland, D., Bjørnerud, A., Gjerstad, L., Wallin, A., Hessen, E., Reinvang, I., Grambaitė, R., Auning, E., Kjærvik, V. K., et al. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-121603 · Cited by 103
McGrattan, A., Pakpahan, E., Siervo, M., Mohan, D., Reidpath, D. D., Prina, M. A., Allotey, P. A., Zhu, Y., Shulin, C., Yates, J., et al. (2022) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12267 · Cited by 103
Clinical criteria for limbic‐predominant age‐related TDP‐43 encephalopathy
Wolk, D. A., Nelson, P. T., Apostolova, L. G., Arfanakis, K., Boyle, P. A., Carlsson, C. M., Corriveau‐Lecavalier, N., Dacks, P. A., Dickerson, B. C., Domoto‐Reilly, K., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.14202 · Cited by 103
Self-citationBessi, V., Mazzeo, S., Padiglioni, S., Piccini, C., Nacmias, B., Sorbi, S., & Bracco, L. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-171180 · Cited by 103
PET Neuroimaging of Alzheimer's Disease: Radiotracers and Their Utility in Clinical Research
Bao, W., Xie, F., Zuo, C., Guan, Y., & Huang, Y. H. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.624330 · Cited by 102
Keeney, J. T.-R., Ibrahimi, S., & Zhao, L. (2015) · Journal of Alzheimer's Disease · doi:10.3233/jad-150348 · Cited by 102
Wood, S. A., & Lichtenberg, P. A. (2016) · Clinical Gerontologist · doi:10.1080/07317115.2016.1203382 · Cited by 102
Hansson, O., Grothe, M. J., Strandberg, T. O., Ohlsson, T. G., Hägerström, D., Jögi, J., Smith, R. A., & Schöll, M. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00167 · Cited by 102
Jones, E. A. A., Gillespie, A. K., Yoon, S. Y., Frank, L. M., & Huang, Y. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.10.056 · Cited by 103
Revolutionizing Alzheimer's disease and clinical trials through biomarkers
Mattsson, N., Carrillo, M. C., Dean, R. A., Devous, M. D., Nikolcheva, T., Pesini, P., Salter, H., Potter, W. Z., Sperling, R. A., Bateman, R. J., et al. (2015) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2015.09.001 · Cited by 102
Self-citationLane, C., Parker, T. D., Cash, D. M., Macpherson, K., Donnachie, E., Murray‐Smith, H., Barnes, A., Barker, S., Beasley, D. G., Brás, J., et al. (2017) · BMC Neurology · doi:10.1186/s12883-017-0846-x · Cited by 102
Estrogen Regulation of Mitochondrial Bioenergetics
Yao, J., & Brinton, R. D. (2012) · Advances in pharmacology · doi:10.1016/b978-0-12-394816-8.00010-6 · Cited by 103
Alzheimer disease pathology and the cerebrospinal fluid proteome
Dayon, L., Núñez Galindo, A., Wojcik, J., Cominetti, O., Corthésy, J., Oikonomidi, A., Henry, H., Kussmann, M., Migliavacca, E., Severin, I., et al. (2018) · Alzheimer's Research & Therapy · doi:10.1186/s13195-018-0397-4 · Cited by 101
Emerging cerebrospinal fluid biomarkers in autosomal dominant Alzheimer's disease
Schindler, S. E., Li, Y., Todd, K. W., Herries, E. M., Henson, R. L., Gray, J. D., Wang, G., Graham, D. L., Shaw, L. M., Trojanowski, J. Q., et al. (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.12.019 · Cited by 101
Self-citationHausdorff, J. M., & Buchman, A. S. (2013) · The Journals of Gerontology Series A · doi:10.1093/gerona/glt002 · Cited by 101
Advances in development of fluorescent probes for detecting amyloid-β aggregates
Xu, M., Ren, W., Tang, X.-C., Hu, Y., & Zhang, H. (2016) · Acta Pharmacologica Sinica · doi:10.1038/aps.2015.155 · Cited by 101
Gerischer, L. M., Fehlner, A., Köbe, T., Prehn, K., Antonenko, D., Grittner, U., Braun, J., Sack, I., & Flöel, A. (2017) · NeuroImage Clinical · doi:10.1016/j.nicl.2017.12.023 · Cited by 101
Grill, J. D., Raman, R., Ernstrom, K. B., Sultzer, D. L., Burns, J. M., Donohue, M., Johnson, K. A., Aisen, P. S. S., Sperling, R. A., Karlawish, J. H., et al. (2020) · JAMA Neurology · doi:10.1001/jamaneurol.2020.2734 · Cited by 101
Self-citationUsing Pittsburgh Compound B for In Vivo PET Imaging of Fibrillar Amyloid-Beta
Cohen, A. D., Rabinovici, G. D., Mathis, C. A., Jagust, W. J., Klunk, W. E., & Ikonomović, M. D. (2012) · Advances in pharmacology · doi:10.1016/b978-0-12-394816-8.00002-7 · Cited by 103
Babiloni, C., Percio, C. D., Bordet, R., Bourriez, J., Bentivoglio, M., Payoux, P., Derambure, P., Dix, S. L., Infarinato, F., Lizio, R., et al. (2012) · Clinical Neurophysiology · doi:10.1016/j.clinph.2012.09.017 · Cited by 101
Mild Cognitive Impairment: A Concept and Diagnostic Entity in Need of Input from Neuropsychology
Bondi, M. W., & Smith, G. E. (2014) · Journal of the International Neuropsychological Society · doi:10.1017/s1355617714000010 · Cited by 101
Podhorná, J., Krahnke, T., Shear, M. A., Harrison, J., & Initiative, A. D. N. (2016) · Alzheimer s Research & Therapy · doi:10.1186/s13195-016-0170-5 · Cited by 101
Scheff, S. W., Ansari, M. A., & Mufson, E. J. (2016) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2016.02.030 · Cited by 100
Thal, D. R., Attems, J., & Ewers, M. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-141461 · Cited by 100
Toward precision medicine in Alzheimer’s disease
Reitz, C. (2016) · Annals of Translational Medicine · doi:10.21037/atm.2016.03.05 · Cited by 100
Hales, C. M., Dammer, E. B., Deng, Q., Duong, D. M., Gearing, M., Troncoso, J. C., Thambisetty, M., Lah, J. J., Shulman, J. M., Levey, A. I., et al. (2016) · PROTEOMICS · doi:10.1002/pmic.201600057 · Cited by 99
Silva, A. R. T., Santos, A. C. F., Farfel, J. M., Grinberg, L. T., Ferretti, R. E. L., Campos, A. H. J. F. M., Cunha, I. W., Begnami, M. D., Rocha, R. M., Carraro, D. M., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0099897 · Cited by 99
Iulita, M. F., Ower, A., Barone, C., Pentz, R., Gubert, P., Romano, C., Cantarella, R. A., Elia, F., Buono, S., Recupero, M., et al. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.05.001 · Cited by 99
Fernández-Blázquez, M. A., Ávila-Villanueva, M., Maestú, F., & Medina, M. (2016) · Journal of Alzheimer's Disease · doi:10.3233/jad-150956 · Cited by 98
Artificial intelligence and neuropsychological measures: the case of Alzheimer's disease
Battista, P., Salvatore, C., Berlingeri, M., Cerasa, A., & Castiglioni, I. (2020) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2020.04.026 · Cited by 98
Metadata
- Authors
- Sperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., Park, D. C., Reiman, E. M., Rowe, C. C., Siemers, E., Stern, Y., Yaffe, K., Carrillo, M. C., Thies, B., Morrison‐Bogorad, M., Wagster, M. V., & Phelps, C. H.
- Affiliations
- Brigham and Women's Hospital (US)
- University of California San Diego (US)
- University of California, Davis (US)
- Rush University Medical Center (US)
- University of Washington (US)
- Washington University in St. Louis (US)
- The University of Tokyo (JP)
- Mayo Clinic (US)
- Oregon Health & Science University (US)
- The University of Texas at Dallas (US)
- Banner Alzheimer’s Institute (US)
- The University of Melbourne (AU)
- Eli Lilly (United States) (US)
- Columbia University Irving Medical Center (US)
- San Francisco VA Medical Center (US)
- Alzheimer's Association Chicago IL USA
- Alzheimer's Association (US)
- National Institutes of Health (US)
- Corresponding author
- Sperling, Reisa A.
- ORCID
- Venue
- Alzheimer's & Dementia
- Publisher
- Wiley
- Published
- 2011-04-22
- Volume
- 7
- Issue
- 3
- Pages
- 280-292
- ISSN
- 1552-5260 (ISSN-L)
- 1552-5279
- PMC
- PMC3220946
- OpenAlex
- W2129497119
- Semantic Scholar
- 4718e61de2c928d77780b2a72fac704f18d8297b
- Cited by
- 7,155
- References
- 71
- Citations by year
- 2026: 375 · 2025: 467 · 2024: 485 · 2023: 445 · 2022: 534 · 2021: 575 · 2020: 550 · 2019: 533 · 2018: 513 · 2017: 471 · 2016: 468 · 2015: 461 · 2014: 417 · 2013: 418 · 2012: 302
- FWCI
- 277.90
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Alzheimer s & Dementia (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Columbia Academic Commons (Columbia University)
- Funders
- National Institute on Aging
- Pfizer
- Baxter International
- Johnson and Johnson
- Eli Lilly and Company
- Bayer
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Oncology › Cancer-related cognitive impairment studies
- Keywords
- Alzheimer's disease, preclinical Alzheimer's disease
- MeSH terms
- Alzheimer Disease, Cognition Disorders, Humans, United States, Biomarkers, Practice Guidelines as Topic, National Institute on Aging (U.S.)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
